Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767990 | 0.95 | CA12 (0.50) | SENP1HSD17B1CA12CA1CA2 | |
| SCHEMBL19763403 | 0.94 | SENP1 (0.50) | SENP1HSD17B1CA12CA1CA2 | |
| SCHEMBL9725239 | 0.93 | ESR1 (0.50) | SENP1HSD17B1CA12CA1CA2 | |
| SCHEMBL19763405 | 0.92 | SENP1 (0.51) | SENP1HSD17B1CA12CA1CA2 | |
| SCHEMBL17826637 | 0.89 | SENP1 (0.46) | SENP1HSD17B1CA12CA1CA2 | |
| SCHEMBL8597105 | 0.89 | KMT2A (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10882053 | 0.87 | ESR1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11341049 | 0.85 | ESR1 (0.62) | ESR1ESR2LMNAMEN1KMT2A | |
| SCHEMBL15582423 | 0.85 | L3MBTL1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17826636 | 0.85 | SENP1 (0.59) | SENP1HSD17B1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404794-B2 | Liquid crystal compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8344175-B2 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120104316-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2440632-A2 | LIQUID CRYSTAL COMPOSITIONS | E. I. du Pont de Nemours and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2440631-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. du Pont de Nemours and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8067068-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8044228-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8034255-B2 | Liquid crystal compositions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-7879256-B2 | bis(meth)acrylates with esters linking mesogen to a flexible spacer and polymerizable (meth)acrylates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2010144393-A2 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144411-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100308268-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2001974-A1 | LIQUID CRYSTAL COMPOSITIONS, POLYMER NETWORKS DERIVED THEREFROM AND PROCESS FOR MAKING THE SAME | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007120458-A1 | LIQUID CRYSTAL COMPOSITIONS, POLYMER NETWORKS DERIVED THEREFROM AND PROCESS FOR MAKING THE SAME | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070228326-A1 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | SENP1 4366/4885HSD17B1 3379/4885CA12 744/4885 |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | TTR, CNOT9, CNOT7 | SENP1 2504/4885HSD17B1 1803/4885CA12 287/4885 |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | AQP3, AQP1, NCAPD2 | SENP1 4207/4885HSD17B1 1185/4885CA12 435/4885 |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | SENP1 4366/4885HSD17B1 3379/4885CA12 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.